US Investigational new drug application (IND) for Sativex®

[MSUK]

US Investigational new drug application (IND) for Sativex® phase 3 clinical program for MS spasticity

GW Pharmaceuticals plc announced today that it has opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex is currently approved in 22 countries outside the U.S. as a treatment for MS spasticity....... Read More - http://www.ms-uk.org/index.cfm/sativex